ES2356880B8 - Liposomas recubiertos con el dominio extracelular de la proteína apo2l/trail. - Google Patents
Liposomas recubiertos con el dominio extracelular de la proteína apo2l/trail. Download PDFInfo
- Publication number
- ES2356880B8 ES2356880B8 ES200930618A ES200930618A ES2356880B8 ES 2356880 B8 ES2356880 B8 ES 2356880B8 ES 200930618 A ES200930618 A ES 200930618A ES 200930618 A ES200930618 A ES 200930618A ES 2356880 B8 ES2356880 B8 ES 2356880B8
- Authority
- ES
- Spain
- Prior art keywords
- apo2l
- extracellular domain
- trail protein
- liposomes
- covered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 102000046283 TNF-Related Apoptosis-Inducing Ligand Human genes 0.000 title abstract 6
- 108700012411 TNFSF10 Proteins 0.000 title abstract 6
- 239000002502 liposome Substances 0.000 title abstract 3
- 239000003814 drug Substances 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Dispersion Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Liposomas recubiertos con el dominio extracelular de la proteína APO2L/TRAIL.#La presente invención se encuadra dentro del campo de la biotecnología y la medicina. Específicamente, la presente invención se refiere a un compuesto que comprende un liposoma recubierto o decorado, al menos, con el dominio extracelular de la proteína APO2L/TRAIL y a su uso para la elaboración de un medicamento, preferiblemente, para el tratamiento de un cáncer o de enfermedades inflamatorias o autoinmunes, como la artritis reumatoide.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200930618A ES2356880B8 (es) | 2009-08-21 | 2009-08-21 | Liposomas recubiertos con el dominio extracelular de la proteína apo2l/trail. |
EP10809583A EP2468260A2 (en) | 2009-08-21 | 2010-08-12 | Liposomes covered with the extracellular domain of the apo2l/trail protein |
PCT/ES2010/000354 WO2011020933A2 (es) | 2009-08-21 | 2010-08-12 | Liposomas recubiertos con el dominio extracelular de la proteína apo2l/trail |
US13/391,582 US20120189690A1 (en) | 2009-08-21 | 2010-08-12 | Liposomes covered with the Extracellular Domain of the APO2L/Trail Protein |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200930618A ES2356880B8 (es) | 2009-08-21 | 2009-08-21 | Liposomas recubiertos con el dominio extracelular de la proteína apo2l/trail. |
Publications (3)
Publication Number | Publication Date |
---|---|
ES2356880A1 ES2356880A1 (es) | 2011-04-14 |
ES2356880B1 ES2356880B1 (es) | 2012-04-23 |
ES2356880B8 true ES2356880B8 (es) | 2012-10-30 |
Family
ID=43607379
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES200930618A Expired - Fee Related ES2356880B8 (es) | 2009-08-21 | 2009-08-21 | Liposomas recubiertos con el dominio extracelular de la proteína apo2l/trail. |
Country Status (4)
Country | Link |
---|---|
US (1) | US20120189690A1 (es) |
EP (1) | EP2468260A2 (es) |
ES (1) | ES2356880B8 (es) |
WO (1) | WO2011020933A2 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015017854A1 (en) * | 2013-08-02 | 2015-02-05 | Cornell University | Method to functionalize cells in human blood, other fluids and tissues using nanoparticles |
IT202000013042A1 (it) * | 2020-06-01 | 2021-12-01 | Univ Degli Studi G Dannunzio Chieti Pescara | Sistema liposomiale con killer tnf-apoptosis induced ligand (killertrail), pro-apoptotico-direzionante. |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4435304B2 (ja) | 1995-06-29 | 2010-03-17 | イミュネックス・コーポレーション | アポトーシスを誘導するサイトカイン |
US6284236B1 (en) * | 1995-06-29 | 2001-09-04 | Immunex Corporation | Cytokine that induces apoptosis |
US6030945A (en) * | 1996-01-09 | 2000-02-29 | Genentech, Inc. | Apo-2 ligand |
AU766984B2 (en) | 1999-09-30 | 2003-10-30 | Trustees Of The University Of Pennsylvania, The | Trail: an inhibitor of autoimmune inflammation and cell cycle progression |
US6444640B1 (en) | 1999-09-30 | 2002-09-03 | Ludwig Institute For Cancer Research | Compositions of trail and DNA damaging drugs and uses thereof |
US20020115613A1 (en) | 2001-02-16 | 2002-08-22 | Kumar M. Vijay | Treatment of prostate cancer |
CA2449873A1 (en) * | 2001-06-07 | 2002-12-12 | Celator Technologies, Inc. | Cell penetrating therapeutic agents |
KR20030026069A (ko) | 2001-09-24 | 2003-03-31 | 주식회사 엘지생명과학 | 티엔에프계 단백질과 플라보피리돌의 조합에 의한 암세포특이적인 세포사멸 유도용 조성물 |
US20050113328A1 (en) | 2003-11-06 | 2005-05-26 | Devi Gayathri R. | Method and antisense compound for potentiating anti-cancer agents |
GB0524316D0 (en) | 2005-11-29 | 2006-01-04 | Medical Res Council | Tumour necrosis factor-related apoptosis-inducing ligands (TRAILs) |
-
2009
- 2009-08-21 ES ES200930618A patent/ES2356880B8/es not_active Expired - Fee Related
-
2010
- 2010-08-12 US US13/391,582 patent/US20120189690A1/en not_active Abandoned
- 2010-08-12 EP EP10809583A patent/EP2468260A2/en not_active Withdrawn
- 2010-08-12 WO PCT/ES2010/000354 patent/WO2011020933A2/es active Application Filing
Also Published As
Publication number | Publication date |
---|---|
EP2468260A2 (en) | 2012-06-27 |
ES2356880A1 (es) | 2011-04-14 |
WO2011020933A8 (es) | 2012-04-05 |
ES2356880B1 (es) | 2012-04-23 |
WO2011020933A3 (es) | 2011-07-14 |
US20120189690A1 (en) | 2012-07-26 |
WO2011020933A2 (es) | 2011-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2013001754A1 (es) | Compuestos derivados de enonas triciclicas y tetraciclicas de pirazolilo y pirimidinilo; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades inflamatorias. | |
CO6910184A2 (es) | Nuevos compuestos para tratamiento de enfermedades asociadas con proteinas amiloides o tipo amiloide | |
CL2013001295A1 (es) | Compuestos derivados de 2,3-dihidromidazo (1,2-c) quinazolina sustituidos con aminoalcoholes; compuesto intermediario y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis. | |
WO2014145159A3 (en) | Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use | |
GT201200313A (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
DE102010039955A8 (de) | Fertigungsanlage zur Herstellung von Faserverbundmaterial-Bauteilen | |
BR112013001875A2 (pt) | cueca masculina com espaço separado para o pênis | |
BR112013009083A2 (pt) | anticorpos humanos de oncostatin m e métodos de uso | |
BR112014028413A2 (pt) | usos terapêuticos de proteínas do fator de crescimento de fibroblastos 21 . | |
BR112012016853A2 (pt) | "composições farmacêuticas para administração oral de peptídeos de insulina". | |
GT201400085A (es) | Profármaco de adrenomedulina basado en polietilenglicol y su uso | |
IN2014DN03213A (es) | ||
EA201400623A1 (ru) | Новые 2h-индазолы в качестве антагонистов рецептора ep | |
IT1400545B1 (it) | Procedimento per la preparazione di tessuto biologico per protesi biologiche. | |
WO2012049307A3 (en) | Novel n-terminally modified insulin derivatives | |
UY33372A (es) | ?análogos de quinolina bi?funcionales, su uso en la manufactura de medicamentos,composiciones que los comprenden y procesos de preparacion?. | |
BR112013015428A2 (pt) | formulações de aerossol com melhores propriedades de pulverização | |
DOP2016000064A (es) | Derivados de fenilalanina sustituidos | |
ECSP13012536A (es) | Composiciones de anticuerpo y métodos de uso | |
FR2965588B1 (fr) | Ensemble propulsif d'aeronef | |
FR2939766B1 (fr) | Pylone central d'aeronef. | |
ES2974721T3 (es) | Intermedios para la preparación de inhibidores del extremo C-terminal de Hsp90 | |
ES2356880B8 (es) | Liposomas recubiertos con el dominio extracelular de la proteína apo2l/trail. | |
IT1401472B1 (it) | Procedimento di fabbricazione di calzature con l'uso di un sistema interattivo | |
FR2956381B1 (fr) | Tracteur d'avion. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 2356880 Country of ref document: ES Kind code of ref document: B1 Effective date: 20120423 |
|
FD2A | Announcement of lapse in spain |
Effective date: 20180924 |